CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who c...
Phase 1
Jacksonville, Florida, United States and 12 other locations
a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple...
Phase 1, Phase 2
Jacksonville, Florida, United States and 12 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Jacksonville, Florida, United States and 59 other locations
progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...
Phase 3
Jacksonville, Florida, United States and 211 other locations
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...
Phase 2
Jacksonville, Florida, United States and 46 other locations
(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...
Phase 2
Jacksonville, Florida, United States and 48 other locations
with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single a...
Phase 1, Phase 2
Jacksonville, Florida, United States and 12 other locations
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...
Phase 3
Jacksonville, Florida, United States and 82 other locations
This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in...
Phase 1, Phase 2
Jacksonville, Florida, United States and 16 other locations
antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...
Phase 1
Jacksonville, Florida, United States and 25 other locations
Clinical trials
Research sites
Resources
Legal